Related Experiment Video
Updated: May 14, 2026

08:58
Label-Free Identification of Lymphocyte Subtypes Using Three-Dimensional Quantitative Phase Imaging and Machine Learning
Published on: November 19, 2018
Two-dimensional matrix algorithm using detrended fluctuation analysis to distinguish Burkitt and diffuse large B-cell
Rong-Guan Yeh1, Chung-Wu Lin, Maysam F Abbod
1Department of Mechanical Engineering, Yuan Ze University, Chungli 32003, Taiwan.
Computational and Mathematical Methods in Medicine
|February 1, 2013
Summary
Detrended fluctuation analysis (DFA) effectively distinguishes Burkitt lymphoma (BL) from diffuse large B-cell lymphoma (DLBCL) in lymph section images. The DFA
Area of Science:
- Medical image analysis
- Hematopathology
- Biophysics
Background:
- Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) exhibit distinct 5-year survival rates post-chemotherapy.
- Accurate differentiation between BL and DLBCL is crucial for effective treatment strategies.
Purpose of the Study:
- To apply a 2-dimensional detrended fluctuation analysis (2D DFA) method for recharacterizing lymph section images.
- To evaluate the efficacy of 2D DFA in distinguishing between BL and DLBCL based on image characteristics.
Main Methods:
- Utilized 2-dimensional detrended fluctuation analysis (2D DFA) on digital images of lymph sections.
- Classified 18 BL images into Group A (1-5 cytogenetic changes) and Group B (>5 cytogenetic changes).
- Classified 10 DLBCL images into Group C.
Main Results:
- The short-term correlation exponent (α1) values for Groups A, B, and C were 0.370 ± 0.033, 0.382 ± 0.022, and 0.435 ± 0.053, respectively.
- A significantly lower α1 value was observed in BL images (Groups A and B) compared to DLBCL images (Group C) (P < 0.05).
- No significant difference in α1 values was found between the two BL groups (A and B).
Conclusions:
- The α1 value derived from 2D DFA statistical analysis can effectively differentiate between BL and DLBCL lymph section images.
- 2D DFA provides a quantitative method for distinguishing aggressive lymphomas with different prognoses.

